GILEAD SCIENCES, INC. 4

Gilead Sciences Chairman & CEO Daniel Patrick O'Day sold a total of 15,000 shares of GILD common stock on August 3, 2026 for about $1.98 million under a Rule 10b5-1 plan.

On August 3, 2026, Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences, Inc., executed three open-market sales of Gilead common stock under a Rule 10b5-1 trading plan adopted on February 25, 2026. He sold 6,700 shares at an average price of approximately $129.66, 7,700 shares at about $130.80, and 600 shares at about $131.34, for total proceeds of roughly $1.98 million. These sales occurred within specified price ranges disclosed in the footnotes and reduced his direct holdings from prior levels to 592,133 shares of Gilead common stock following the transactions.

Filing Facts

CIK

882095

Ticker

GILD

Form

4

Source Type

fda

Accession

0001638643-26-000028

Alert Tier

9